family with sequence similarity 225 member BGenealiases: C9orf110 · LINC00256B · NCRNA00256B
Q-omics provides the consensus-scored FAM225B profile across patient tissues and cancer cell-line models. FAM225B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM225B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, FAM225B RNA expression shows 15,220 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where FAM225B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM225B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM225B survival associations across molecular data types. FAM225B RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM225B RNA expression–survival associations across cancer types. High FAM225B expression shows unfavorable associations in ACC, KIRC, KICH, KIRP, THCA and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM225B RNA expression.
This table summarizes FAM225B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM225B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM225B shows higher tumor expression in HNSC, LUAD, STAD, KIRC, COAD and LIHC. The HNSC box plot shows higher FAM225B RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p < 0.001).
This table shows molecular features associated with FAM225B in patient tissues and cancer cell lines. In patient samples, FAM225B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
